Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Consensus Target Price from Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have received an average rating of “Buy” from the nine analysts that are covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $7.43.

Several equities research analysts have recently weighed in on TRVI shares. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Tuesday. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, August 19th. Leerink Partnrs raised Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Raymond James started coverage on Trevi Therapeutics in a research note on Friday, August 30th. They issued an “outperform” rating and a $9.00 price objective on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research note on Friday, October 4th.

Trevi Therapeutics Price Performance

Shares of TRVI stock opened at $3.12 on Friday. Trevi Therapeutics has a 1 year low of $0.97 and a 1 year high of $4.00. The stock’s 50 day simple moving average is $3.13 and its two-hundred day simple moving average is $2.89. The company has a market cap of $219.76 million, a PE ratio of -9.18 and a beta of 0.97.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same quarter last year, the firm posted ($0.07) earnings per share. Equities research analysts expect that Trevi Therapeutics will post -0.47 EPS for the current year.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the sale, the insider now owns 220,315 shares of the company’s stock, valued at approximately $608,069.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Thomas Sciascia sold 18,660 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the sale, the insider now owns 220,315 shares of the company’s stock, valued at $608,069.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $644,205.26. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,355 shares of company stock valued at $116,663. 24.37% of the stock is currently owned by corporate insiders.

Institutional Trading of Trevi Therapeutics

Institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD acquired a new stake in shares of Trevi Therapeutics in the 1st quarter worth $47,000. Hsbc Holdings PLC acquired a new stake in shares of Trevi Therapeutics in the 2nd quarter worth $61,000. SG Americas Securities LLC purchased a new position in Trevi Therapeutics in the 3rd quarter worth $78,000. The Manufacturers Life Insurance Company raised its stake in Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after acquiring an additional 11,450 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Trevi Therapeutics by 17.1% in the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after acquiring an additional 7,902 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.